#United States #New York #Class Action #Gross Law Firm #Gossamer Bio

Gossamer Bio, Inc. Faces Class Action Lawsuit: Important Information for Shareholders

The Gross Law Firm has officially notified investors in Gossamer Bio, Inc. (NASDAQ: GOSS) about a forthcoming class action lawsuit, urging those who held shares during the specified period to engage with the firm. The deadline to apply for lead plaintiff status in this lawsuit is set for June 1, 2026.

Key Details of the Lawsuit

The class period for this action spans from June 16, 2025, to February 20, 2026. Investors are encouraged to reach out to the Gross Law Firm, even if they do not wish to take on the lead plaintiff role, as participation in this recovery does not require it.

Allegations Against Gossamer Bio

The lawsuit outlines serious allegations against Gossamer Bio, claiming that company officials made excessively optimistic statements to the public while simultaneously hiding material negative facts regarding their Phase 3 PROSERA study.

Specifically, the complaint asserts that the company did not adequately control for the placebo response at its testing sites located in Latin America, which misled investors about the study's outcomes. On February 23, 2026, when Gossamer announced the topline results of this study, the news was disappointing, revealing that the company did not meet its primary endpoint for improved six-minute walk distance (6MWD) at Week 24. With a meager +13.3 meter placebo-adjusted gain, the results fell short of the threshold for statistical significance, further causing alarm among investors.

Stock Price Impact

Following these revelations, Gossamer Bio's stock witnessed a massive decline, plummeting from a closing price of $2.13 per share as of February 20, 2026, to just $0.42 per share on February 23, reflecting a staggering drop of over 80% in just one day. This drop has raised significant concerns about the leadership and decision-making within the company, prompting shareholders to seek accountability through legal channels.

How to Proceed as a Shareholder

Gossamer Bio shareholders who purchased shares during the specified class action period are strongly advised not to delay in registering for participation. Those interested can submit their details via the following link: Gossamer Bio Loss Submission Form.

Upon registration, shareholders will gain access to monitoring software that tracks the case's progress, keeping them informed throughout its duration. Importantly, participating in this case incurs no cost or obligation for shareholders.

Why Choose Gross Law Firm?

The Gross Law Firm stands out as a nationally recognized entity that specializes in class action lawsuits. Its core mission is to safeguard the rights of investors who have faced challenges due to fraudulent activities and dishonest practices in the business sector. The firm is dedicated to ensuring that companies remain accountable and conduct their operations ethically, thus supporting shareholders through financial recoveries with integrity.

For further assistance, shareholders can contact the Gross Law Firm directly:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

In conclusion, Gossamer Bio, Inc. shareholders need to act quickly in light of these urgent developments. The looming class action lawsuit is an essential step towards ensuring that responsible practices are upheld within the company, as they seek to uphold their rights in the midst of these challenges.